TScan Therapeutics (NASDAQ:TCRX) Lowered to “Hold” Rating by Lifesci Capital

TScan Therapeutics (NASDAQ:TCRX) was downgraded by research analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks reports.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. HC Wainwright reiterated a “buy” rating on shares of TScan Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a report on Friday, July 17th. Finally, Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a report on Thursday, August 13th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.67.

TScan Therapeutics Price Performance

TCRX opened at $0.37 on Wednesday. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31. The company’s 50-day moving average price is $0.84 and its 200 day moving average price is $0.98. TScan Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $2.57. The firm has a market cap of $25.14 million, a price-to-earnings ratio of -0.41 and a beta of 1.07.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.88 million. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%. As a group, sell-side analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $36,000. Bank of America Corp DE acquired a new position in TScan Therapeutics during the 2nd quarter worth $48,000. Landscape Capital Management L.L.C. acquired a new position in TScan Therapeutics during the 2nd quarter worth $25,000. NewEdge Wealth LLC bought a new position in shares of TScan Therapeutics in the second quarter worth $90,000. Finally, BlackRock Inc. bought a new position in shares of TScan Therapeutics in the second quarter worth $975,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.